COMMUNIQUÉS West-GlobeNewswire

Additional agenda item for Annual General Meeting of shareholders of Joint Stock Company Olainfarm to be held on June 17th, 2019
27/05/2019
Joint Stock Company Olainfarm (unitary registration No. 40003007246, legal address: Rupnicu street 5, Olaine, LV-2114) Management Board hereby informs, that the following additional item is included in the agenda of [...]
JSC Olainfarm invites to Investor Conference - Webinar to present 1st Quarter 2019 results and the company’s new management
27/05/2019
JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on June 5, 2019 at 16:00 (EET). To join the webinar please follow the [...]
Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences
27/05/2019
Press release – No. 12 / 2019 Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences Copenhagen, May 27, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac, Chief Medical and [...]
Ossur Hf : Major shareholder announcement
27/05/2019
Announcement 34/2019 See enclosed Major shareholder announcement. Attachment Major shareholder announcement.pdf
Ventura Cannabis (VCAN) Updates Investor Presentation After Reaching Several Milestones; Adds Senior Managers to Support Growth Plan; Announces Investor Meetings in Toronto
27/05/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ALL FIGURES IN CANADIAN DOLLARS UNLESS OTHERWISE SPECIFIED. LOS ANGELES, May 27, 2019 (GLOBE NEWSWIRE) -- Ventura [...]
Emerald Completes Issuance of Shares in Lieu of Cash Due for Verdélite Acquisition
27/05/2019
VANCOUVER, British Columbia, May 27, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and [...]
Ossur Hf : Major shareholder announcement
27/05/2019
Announcement 33/2019 See enclosed Major shareholder announcement. Attachment Major shareholder announcement.pdf
Share buy-back week 21/2019
27/05/2019
Announcement 27 May 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Auxly Reports Q1 2019 Financial Results and Highlights Key Milestones
27/05/2019
VANCOUVER, British Columbia, May 27, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (OTCQX: CBWTF) (" Auxly " or the " Company ") today released its financial results for the three months ended March [...]
Sequana Medical Announces Presentation of Positive DSR Clinical Proof-of-Concept Data Demonstrating Potential in Volume Overload Due to Heart Failure
27/05/2019
First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher sodium removal with DSR vs standard Peritoneal Dialysis (PD) [...]
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
27/05/2019
Pratteln, Switzerland, May 27, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) for Puldysa® (idebenone) for the treatment of respiratory [...]
BOAZ Pharmaceuticals Inc. Celebrates Sales Licence Granted In Record Time
25/05/2019
Passionate Team of Homegrown Heroes Proves Size Doesn’t Matter CALGARY, Alberta, May 24, 2019 (GLOBE NEWSWIRE) -- BOAZ Pharmaceuticals Inc. is now licensed to sell handcrafted cannabis in Canada to medical clients and [...]
Aptose Biosciences Establishes New At-The-Market Facility
24/05/2019
SAN DIEGO and TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
WALTHAM, Mass. and CRESTWOOD, Ky., May 24, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
24/05/2019
Montrouge, France, May 24, 2019 DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors Shareholders approve all proposed [...]
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2019, ainsi que la nomination de Madame Viviane Monges en tant que membre du conseil d’administration
24/05/2019
Montrouge, France, le 24 Mai 2019 (22h30 CET) DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2019, ainsi que la nomination de Madame Viviane Monges en tant que membre du [...]
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24/05/2019
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone in the SOLAR-1 [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
BOTHELL, Wash., May 24, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
24/05/2019
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies expected over next three quarters- [...]

Pages